Thomas R. Staab II
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Thomas R. Staab II
Thomas R. Staab II is recorded as CFO at Biocryst Pharmaceuticals Inc (BCRX). The proxy statement of Biocryst Pharmaceuticals Inc reports total compensation of $692,790 for Thomas R. Staab II in fiscal 2020, including a base salary of $77,113. Disclosed compensation is on record for 4 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Biocryst Pharmaceuticals Inc
Other people whose current roles at this company are on record from its filings.
- Charles Gayer CEO, Board Member
- Charlie Gayer CEO, Board Member
- Jon P. Stonehouse CEO, CFO, Chief Accounting Officer, Board Member
- Vincent J. Milano Chairman, Board Member
- Anthony Doyle CFO
- Babar Ghias CFO, Chief Accounting Officer
- A. Machelle Sanders Board Member
- Alan G. Levin Board Member
- Amy E. McKee Board Member
- Amy E. McKee, M.D. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2020 | Biocryst Pharmaceuticals Inc (BCRX) | Former Senior Vice President and Chief Financial Officer | $77,113 | $692,790 |
| 2019 | Biocryst Pharmaceuticals Inc (BCRX) | Former Senior Vice President and Chief Financial Officer | $462,679 | $910,354 |
| 2018 | Biocryst Pharmaceuticals Inc (BCRX) | Former Senior Vice President and Chief Financial Officer | $449,203 | $1,797,270 |
| 2017 | Biocryst Pharmaceuticals Inc (BCRX) | Senior Vice President and Chief Financial Officer | $434,002 | $1,723,588 |
Recent activity
No call appearances or filed executive changes recorded yet.